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Abstract objective Medication adherence is often suboptimal for adolescents with HIV, and establishing
correct weight-based antiretroviral therapy dosing is difficult, contributing to virological failure. This
review aimed to determine the proportion of adolescents achieving virological suppression after
initiating ART.
methods MEDLINE, EMBASE and Web of Science databases were searched. Studies published
between January 2004 and September 2014 including ≥50 adolescents taking ART and reporting on
the proportion of virological suppressed participants were included.
results From a total of 5316 potentially relevant citations, 20 studies were included. Only eight
studies reported the proportion of adolescents that were virologically suppressed at a specified time
point. The proportion of adolescents with virological suppression at 12 months ranged from 27 to
89%.
conclusion Adolescent achievement of HIV virological suppression was highly variable. Improved
reporting of virological outcomes from a wider range of settings is required to support efforts to
improve HIV care and treatment for adolescents.
keywords Adolescents, HIV, virological suppression
Introduction
An estimated 2.1 million adolescents (10–19 years of
age) globally were living with HIV in 2012 [1]. HIV-
related deaths among adolescents are estimated to have
tripled since 2000, making HIV the second leading cause
of death among adolescents worldwide [2]. Coverage of
antiretroviral therapy (ART) is significantly lower (34%)
in adolescents and children than in adults [3]. With suc-
cessful scale-up of screening and treatment of infants
infected with HIV, many of the >500 000 HIV-infected
children who started on ART during infancy are surviv-
ing to adolescence, often with complex treatment needs.
Adolescence is accompanied by rapid physical, psycho-
logical and physiological changes which influence health-
related behaviour. Adolescents frequently find consistent,
long-term medication adherence difficult, and HIV treat-
ment is no exception [4–6]. Maintaining sustained high
levels of adherence to ART is the crux of successful treat-
ment, preventing the development of drug resistance and
disease progression, and decreasing risk of onward trans-
mission once sexual debut occurs. Virological failure may
also occur as a result of suboptimal drug dosing. Accu-
rate weight-based dosing is difficult to achieve during the
growth spurt which occurs in adolescence, and frequent
dose changes are necessary, which may be challenging in
under-staffed healthcare facilities in low-resource settings,
where the majority of HIV-infected adolescents live, and
can be confusing for the patient.
This review aimed to assess the proportion of adoles-
cents taking ART in routine healthcare settings who
achieve virological suppression in order to inform the
need for interventions to optimise HIV outcomes in an
age group that may be at high risk of treatment failure.
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Methods
This review was conducted in accordance with the stan-
dards of the Preferred Reporting Items for Systematic
Reviews and Meta-Analyses (PRISMA) group [7]. A
detailed protocol was prepared. We included cohort stud-
ies, randomised controlled trials (RCTs) and cross-sec-
tional studies of adolescents taking ART that investigated
the prevalence and/or rate of virological suppression.
Studies were included if they reported on least 50 HIV-
infected adolescents (aged 10–19 years) receiving ART,
or where the mean or median age of participants was
between 10 and 19 years. Studies where neither the mean
nor the median age was reported, or where data were not
disaggregated by age, were excluded. No exclusions with
regard to language or geographical area were applied.
A compound search strategy was developed (Table S1),
and the following electronic databases were searched:
Medline (OVID), Embase (OVID), Global Health (OVID)
and Web of Science. Reference lists of all studies identified
by the above methods, and bibliographies of relevant sys-
tematic reviews or meta-analyses were examined. All refer-
ences were imported into EndNote (Thompson Reuters),
and duplicates were removed. Titles and abstracts were
examined independently by two reviewers (RF and KK) to
exclude studies that clearly did not meet inclusion criteria.
The full text of all potentially relevant studies was
obtained, and the inclusion criteria were applied using a
pre-tested eligibility form. Data extraction was indepen-
dently performed by two reviewers (RF and KK) using a
standardised data extraction form. The following infor-
mation was obtained for included studies: start and end
dates of the study; study design; location (country,
healthcare setting); rate/proportion of participants who
died or were lost to follow-up; age; sex; CD4 cell count
at ART initiation; ART regimen; median duration of fol-
low-up; median duration on ART; laboratory method for
HIV viral load measurement; viral load threshold used to
define suppression; proportion of participants with viral
load ascertained; proportion of participants with virologi-
cal suppression at 12, 24, 36 months; and overall propor-
tion with virological suppression.
Primary outcomes were proportions of adolescents with
suppressed viral load at 12 and 24 months of starting ART.
Secondary outcomes included proportion with virological
suppression irrespective of time on ART and rate of virolog-
ical suppression. Virological suppression was defined as by
the definitions used by the authors of the study.
A modified Newcastle-Ottawa Scale was used to assess
the risk of bias [8]. A scoring scale to evaluate potential
sources of bias was used. It included risk of selection
bias; method of viral load testing; recording of baseline
characteristics; duration of ART and follow-up; propor-
tion of participants with missing outcomes; and appropri-
ateness of analysis. Studies were scored on each these
criteria with studies graded as providing good (score
7–8), moderate (score 5–6) or low quality of evidence
(3–4), or serious risk of bias (<3).
Results
From a total of 5316 potentially relevant unique citations,
20 studies were included in this review (Figure S1). Of the
20 studies that were included, 7 (35%) were from Africa
[9–15], 8 (40%) were from North America [16–19] and
Europe [20–23], 3 (15%) were from Asia [24–26] and 2
(10%) were from Latin America [27, 28] (Table 1). Half
(n = 10) were cohort studies, and half were cross-sectional
studies (n = 10). The studies were predominantly based on
multicentre and/or multicountry research cohorts, or from
urban, specialist centres. The cohorts included perinatally,
sexually and parenterally infected adolescents.
Only eight studies reported the proportion of adoles-
cents that were virologically suppressed at a specified
time point: six [9–12, 21, 23], two [12, 15] and one [19]
study reported the proportion who were virologically
suppressed at 12, 24 and 36 months after ART initiation,
respectively (Table 2). The remainder of the studies pro-
vided an overall proportion of virologically suppressed
adolescents among those in care, without taking the
duration of ART treatment into account.
In the six studies that reported this, the proportion of
adolescents with virological suppression at 12 months
after ART initiation varied from 27% to 89% (Table 2).
Virological suppression rates in studies not stratified by
duration on ART ranged between 28% and 87%.
Approximately one-third of studies (n = 8) neither
reported on the median duration on ART, nor on the
median duration of follow-up [9, 14–16, 18, 19, 22, 23].
Four studies [15, 17, 18, 21] did not record the complete-
ness of outcome data, and two studies had a very high
proportion of missing viral load data (79% and 63%)
[10, 19]. Overall most studies were scored as being mod-
erate or low quality (Table 2).
Discussion
The main finding of this study was the paucity of data on
virological outcomes among adolescents with HIV,
despite more than 15 years of availability of combination
ART. In included studies, there was substantial variation
in the proportion of adolescents achieving virological
suppression, and accurate overall estimates of the effec-
tiveness of ART on viral suppression in this age group
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cannot be drawn because of this variability and the low
to moderate quality of most studies. Thus, a meta-analy-
sis providing a pooled effect estimate was not attempted.
The studies included in this review illustrate some of the
specific methodological issues encountered when analysing
ART outcomes in children and adolescents, but also more
general issues around analysis and reporting of ART out-
comes. Any observational cohort study should be reported
according to the STROBE (strengthening the reporting of
observational studies in epidemiology) checklist, which has
been endorsed by many high impact journals [29, 30]. The
STROBE checklist recommends that for each explanatory
and outcome variable, the source of data and the methods
of assessment (measurement) are described, the number of
individuals at each stage of the study is clearly reported
and the time of follow-up is provided. Furthermore, the
number of participants with missing data should be
recorded and confounders taken into account [31]. Most
of the studies included in this review did not provide all
this information, hindering our ability to accurately iden-
tify the proportion of adolescents succeeding on ART. The
responsibility of accurate reporting lies not only with the
authors, but also with the wider scientific community
including journal editors and peer reviewers. Some of the
studies included in this review were published before the
STROBE checklist was developed.
Even more critical is the fact that a number of the
included cross-sectional studies provided point estimates of
viral load suppression without stratifying the results by time
on ART. Several of these studies did not even report the
mean or median time on ART [14, 16–18, 22]. Time on
ART is highly likely to act as a confounder and cohorts with
similar success rates, but different follow-up times will
appear to have different virological suppression rates. Thus,
unstratified point prevalence estimates of virological sup-
pression are meaningless, and we urge researchers to report
results stratified by duration on ART in all future studies.
All included studies classified participants as adoles-
cents according to their age at initiation of ART. A child
starting ART on their eighth birthday will enter adoles-
cence two years after ART initiation, whereas a child
who starts ART at 6 months of age will have been on
ART for 9.5 years before entering adolescence. Age-
updated analysis is therefore especially important when
examining outcomes in children and adolescents. None of
the studies included in the review attempted an age-
updated analysis. In practice, clinicians want to know the
likelihood of virological suppression of a 14-year old
who has been taking ART for a few months, several
years or over a decade. Clinicians are unlikely to assess
patients aged 14 on the basis of having started ART as a
child aged 1 year, 8 years or as adolescents aged 13. ThisT
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information can only be obtained if age-updated analyses
are performed, alongside the analyses stratified by time
on treatment discussed above.
A total of 21 studies included more than 50 adoles-
cents on ART and reported on virological suppression,
but did not provide adolescent-specific suppression esti-
mates but analysed adolescents together with children,
which meant they had to be excluded. These studies
could have contributed substantially to the body of evi-
dence if age-specific estimates had been provided. Fur-
thermore, systematic reviews focus on peer-reviewed
published studies and thus are subject to publication bias.
Due to heterogeneity of study designs and outcome defi-
nitions, summary estimates could not be calculated. Viral
load testing methods have evolved over time, which
makes comparison of studies across different periods and
settings challenging. Further limitations of this review are
the quality of studies included and high levels of missing
data in some studies.
In conclusion, most available estimates of viral load
suppression in adolescents are not very informative due
to serious methodological concerns. Authors, journals
and peer reviewers should be encouraged to follow the
recommendation for observational cohort studies as laid
out by the STROBE statement. We recommend the devel-
opment of guidelines for ART cohort reporting focused
on children, and adolescents to ensure data are analysed
using generally accepted age groups such as 0, 1–4, 5–9,
10–14, 15–19 years, that time on ART is taken into
account through stratified analyses, and that age-updated
analyses are conducted.
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